G1 Therapeutics, Inc. (GTHX) is a clinical-stage company developing first-in-class drug candidates that are potentially best-in-class in multiple oncology indications. The company's lead candidate is a CDK4/6 inhibitor known as trilaciclib, which is in the same class of drugs as Pfizer's (PFE) Ibrance and Eli Lilly's (LLY) Verzenio, first approved in 2015 and 2017, respectively. Novartis's (NVS) CDK4/6 inhibitor Kisqali is also approved. However, trilaciclib is targeting another vast market and is a first-in-class myelopreservation agent designed to improve patient outcomes by protecting the bone marrow from damage by